THERAPY DOSSIER · th-fac4fed50c0f

Descent to lower simulated altitude (4,500 m or 3,000 m)

Procedure · Physical/environmental procedure; no ChEMBL entity by definition.

Evidence & regulatory context

Mechanism: Physical/environmental procedure; no ChEMBL entity by definition.
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06310642 ↗PHASE4completed

Prospective single-blinded randomised field-based trial of prophylactic oral prochlorperazine for acute mountain sickness (immediate descent from altitude listed as an intervention arm)

AMS · Acute Mountain Sickness

Enrolment: 30 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30651871 ↗2018Reported benefit

Effects of altitude changes on mild-to-moderate closed-head injury in rats following acute high-altitude exposure.

RatTBIClosed-head / concussionFollowing injury, with assessment at 6, 12 and 24 h

Model: Mild-to-moderate closed-head injury induced after simulated acute high-altitude exposure at 6,000 m above sea level

Brain injury was significantly reversed following descent to 4,500 m compared with 6,000 m or 3,000 m, and avoiding large-span descent reduced neurological impairment.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…